IL6 and prostate carcinoma: Thus, immunotherapies focused on the inhibition of either MDSCs recruitment or the inhibition of other mediators that sustain MDSCs immunosuppressive effect (e.g., IL-6 and IL-23) can be a promising therapeutic strategy for prostate cancer patients.